粒细胞集落刺激因子用于急性心肌梗死干细胞动员的随机对照试验
STEM-AMI OUTCOME 是一项前瞻性、多中心、全国性、随机、开放标签、III 期试验,旨在评估早期给予粒细胞集落刺激因子(G-CSF)能否降低大面积 ST 段抬高型心肌梗死(STEMI)患者经皮冠状动脉介入治疗(PCI)后左心室功能不全(LVEF≤45%)的 2 年心脏死亡率和发病率。因招募和事件率低,研究提前终止且统计效能不足;G-CSF 组(n=260)与标准治疗组(n=261)在复合主要终点(全因死亡、再发心肌梗死、心力衰竭住院)上无差异(HR 1.20;95%CI 0.63–2.28),2 年死亡率分别为 2.31% 和 2.68%(HR 0.88;95%CI 0.29–2.60)。
要点
- G-CSF 未显著改善 STEMI 后 LVEF≤45% 患者的复合主要终点。
- G-CSF 组与标准治疗组不良事件无差异(OR 1.17;95%CI 0.78–1.75)。
- 事后分析提示低骨髓细胞动员者复合终点有减少趋势(HR 2.86;95%CI 0.96–8.56)。
核心结论
- 尽管结果不确定,该试验是 STEMI 后细胞修复领域最大规模的试验,提供了 G-CSF 耐受性和长期安全性的证据。
- 结果提示需进一步研究以明确哪些患者从骨髓细胞动员中获益最大。
研究设计与样本
- 前瞻性、多中心、全国性、随机、开放标签、III 期试验(NCT01969890)。
- 纳入 PCI 后 LVEF≤45% 的大面积 STEMI 患者,随机分配至 G-CSF 组(n=260)或标准治疗组(n=261)。
- 主要终点为全因死亡、再发心肌梗死和心力衰竭住院的复合终点。
- 因招募和事件率低,研究提前终止,未达到验证假设的足够统计效能。
主要发现
- 复合主要终点两组无差异(HR 1.20;95%CI 0.63–2.28)。
- 2 年死亡率 G-CSF 组 2.31%,对照组 2.68%(HR 0.88;95%CI 0.29–2.60)。
- 不良事件 G-CSF 组(n=65)与标准治疗组(n=58)无差异(OR 1.17;95%CI 0.78–1.75)。
- 事后分析:低骨髓细胞动员组(n=108)较高动员组(n=152,峰值白细胞计数>50×10^9/L)复合主要终点有减少趋势(HR 2.86;95%CI 0.96–8.56)。
- 事后分析:出院时严重左心室收缩功能不全且接受 G-CSF 治疗的患者主要终点低于对照组(交互作用 β±SE,-0.08±0.04;p=0.034)。
关键数值与推荐
- 主要终点复合结局 HR 1.20(95%CI 0.63–2.28)。
- 2 年死亡率 HR 0.88(95%CI 0.29–2.60)。
- 不良事件 OR 1.17(95%CI 0.78–1.75)。
- 低动员 vs 高动员复合终点 HR 2.86(95%CI 0.96–8.56)。
- 严重 LV 收缩功能不全交互作用 β±SE,-0.08±0.04;p=0.034。
临床怎么用
- 目前证据不支持在 STEMI 后 LV 功能不全患者中常规使用 G-CSF 进行干细胞动员。
- G-CSF 在该人群中显示可耐受和长期安全性,但需进一步研究筛选可能获益的患者。
局限性
- 因招募和事件率低提前终止,统计效能不足。
- 开放标签设计。
- 事后分析结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To determine whether granulocyte colony-stimulating factor (G-CSF) improves clinical outcomes after large ST-elevation myocardial infarction (STEMI) when administered early in patients with left ventricular (LV) dysfunction after successful percutaneous coronary intervention (PCI). METHODS: STEM-AMI OUTCOME was designed as a prospective, multicentre, nationwide, randomised, open-label, phase III trial (ClinicalTrials.gov ID: NCT01969890) to demonstrate the efficacy and safety of early G-CSF administration in reducing 2-year cardiac mortality and morbidity in patients with STEMI with LV ejection fraction ≤45% after PCI. The primary outcome was a composite of all-cause death, recurrence of myocardial infarction and hospitalisation for heart failure. Due to low recruitment and event rates, the study was discontinued and did not achieve adequate statistical power to verify the hypothesis. RESULTS: Patients were randomly allocated to G-CSF (n=260) or standard of care (SOC; n=261). No difference was found in the composite primary outcome between study groups (HR 1.20; 95% CI 0.63 to 2.28). The 2-year mortality was 2.31% in the G-CSF and 2.68% in the control group (HR 0.88; 95% CI 0.29 to 2.60). Adverse events did not differ between the G-CSF (n=65) and SOC groups (n=58; OR 1.17; 95% CI 0.78 to 1.75). In post hoc analyses on the intervention group, we observed a trend towards fewer composite primary outcomes in patients with low bone marrow (BM) cell mobilisation (n=108) versus those with high mobilisation (n=152, with peak leucocyte count >50×109/L; HR 2.86; 95% CI 0.96 to 8.56). Primary outcomes were lower in patients with severe LV systolic dysfunction at discharge treated with G-CSF than in controls (interaction β±SE, -0.08±0.04; p=0.034). CONCLUSIONS: Although inconclusive, this is the largest trial in the field of cell-based cardiac repair after STEMI providing evidence of the tolerability and long-term safety of G-CSF treatment. The results prompt further studies to understand which patient can benefit most from BM cell mobilisation. TRIAL REGISTRATION NUMBER: NCT01969890.
引用
- Achilli, Maggiolini, Madotto, et al. Granulocyte colony-stimulating factor for stem cell mobilisation in acute myocardial infarction: a randomised controlled trial. Heart. 2024. PMID: 39401872. doi:10.1136/heartjnl-2024-323926
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。